Table 4 Antitumour efficacy
Dose level 1 | Dose level 2 | Dose level 3 | Dose level 4 | Total | |
|---|---|---|---|---|---|
Response | (n =6) | (n =6) | (n =9) | (n =4) | (n =25) |
Complete response (CR) | 0 | 0 | 0 | 0 | 0 |
Partial response (PR) | 2 | 4 | 7 | 2 | 15 |
Stable disease (SD) | 1 | 0 | 1 | 0 | 2 |
Progressive disease | 2 | 1 | 0 | 1 | 4 |
Not assessable | 1 | 1 | 1 | 1 | 4 |
Objective response ratea | 71% | ||||
Clinical benefit (CR+PR+SD)a | 81% |
